Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
about
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guidelineHigh density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular riskResidual macrovascular risk in 2013: what have we learned?Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemiaLipids, menopause, and early atherosclerosis in Study of Women's Health Across the Nation Heart women.Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trialHigh density lipoprotein and cardiovascular diseases.The metabolism and anti-atherogenic properties of HDL.Metabolic syndrome: nature, therapeutic solutions and options.Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.Novel metabolic biomarkers of cardiovascular disease.The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.New and emerging biomarkers in cardiovascular disease.Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.PPARα-dependent increase of mouse urine output by gemfibrozil and fenofibrate.Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond.[HDL: the yin-yang of cardiovascular disease].Cardiovascular Risk Factor Burden in Veterans and Non-Veterans with Parkinson Disease.
P2860
Q24608464-C499FCD4-D514-49F0-BD9B-F62296C04FB9Q26775420-84AE9EF0-BCCB-408C-BD88-E58584DB4C8CQ26996039-3214DF4B-0624-477F-85A7-028514474BDFQ33988254-4F513786-070A-43FD-8D64-89DB2E6236E1Q35068678-81BFBFDE-7852-4037-87DB-9FD2E6B94A17Q36366340-4CDE3E2A-0785-4D64-9AAB-4CCF2BB7EC6DQ36730543-ED66CBA4-64EC-42DC-9BE8-014D2170C7B1Q37043222-32AA502C-580B-4AA8-A344-838A8FEA4A37Q37334590-67484923-8B60-483A-ADD1-6826289DD3BEQ37901053-EDDC300C-B14F-49B2-BAFE-CA51B9830CA3Q38051303-4DC8351E-8543-4FF0-AC3E-D476CAF222CDQ38245327-9F5B9BD7-5F0D-45E9-95A8-0FF88289DEACQ38273378-05720223-C536-45A6-BB7D-6B1D8C11430AQ38586900-324376B0-3612-45B4-AB11-71D192A4562CQ39029837-40F0440C-DED7-4E40-8C29-AA8381787116Q39130668-A17D22C5-B02A-4216-9D8E-E1B1178696E6Q42055383-3767BE5E-7095-48B6-B8E9-F0A062525A09Q42749585-745CB2E5-1741-46BE-B55B-EF4B2FEDCCA5Q55221906-3AABEE90-849B-4951-BED4-59D342A911CC
P2860
Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Relation of gemfibrozil treatm ...... ipoprotein Intervention Trial.
@ast
Relation of gemfibrozil treatm ...... ipoprotein Intervention Trial.
@en
type
label
Relation of gemfibrozil treatm ...... ipoprotein Intervention Trial.
@ast
Relation of gemfibrozil treatm ...... ipoprotein Intervention Trial.
@en
prefLabel
Relation of gemfibrozil treatm ...... ipoprotein Intervention Trial.
@ast
Relation of gemfibrozil treatm ...... ipoprotein Intervention Trial.
@en
P2093
P2860
P921
P1433
P1476
Relation of gemfibrozil treatm ...... Lipoprotein Intervention Trial
@en
P2093
Bela F Asztalos
Dorothea Collins
Ernst J Schaefer
Katalin V Horvath
Sander J Robins
P2860
P356
10.1016/J.METABOL.2007.08.009
P577
2008-01-01T00:00:00Z